Atea Pharmaceuticals, Inc. (AVIR): Total Liabilities
$39.78M
As of 2025-12-31
+15.0%
3-year compound annual growth
-33.9%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $39.78M | +54.2% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $25.80M | -35.1% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $39.78M | +52.2% | 2025-03-06, Balance as of period end |
| 2022-12-31 | $26.14M | -58.4% | 2024-02-28, Balance as of period end |
| 2021-12-31 | $62.81M | -80.1% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $315.83M | n/m | 2022-02-28, Balance as of period end |
| 2019-12-31 | $2.53M | n/a | 2021-03-30, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | 2025-12-31 | $39.78M | +54.2% |
| LB Pharmaceuticals Inc (LBRX) | 2025-12-31 | $11.62M | -15.9% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $508.98M | -3.0% |
| Sionna Therapeutics, Inc. (SION) | 2025-12-31 | $19.12M | +0.1% |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | $46.33M | -23.0% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $213.39M | +126.2% |
| Liquidia Corp (LQDA) | 2025-12-31 | $283.19M | +87.6% |
| Rocket Pharmaceuticals, Inc. (RCKT) | 2025-12-31 | $53.23M | -17.4% |
| Amylyx Pharmaceuticals, Inc. (AMLX) | 2025-12-31 | $27.39M | -5.1% |
Compare AVIR, LBRX, ADCT, SION side by side · Screen every company in Pharmaceutical Preparations ↗